HomeMNKD • NASDAQ
MannKind Corp
add
$5.02
1.41%
After Hours:(1.79%)-0.090
$4.93
Closed: Apr 2, 5:07:35 PM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 76.78M | 31.30% |
Operating expense | 35.11M | 17.93% |
Net income | 7.42M | 429.76% |
Net profit margin | 9.67 | 302.92% |
Earnings per share | — | — |
EBITDA | 24.22M | 104.25% |
Effective tax rate | 12.11% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 203.56M | -32.60% |
Total assets | 393.84M | -17.12% |
Total liabilities | 472.66M | -34.48% |
Total equity | -78.82M | — |
Shares outstanding | 303.59M | — |
Price to book | -19.04 | — |
Return on assets | 12.86% | — |
Return on capital | 52.03% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 7.42M | 429.76% |
Cash from operations | 22.64M | 4.46% |
Cash from investing | 48.22M | 710.82% |
Cash from financing | -86.90M | -161.33% |
Net change in cash | -16.03M | -110.31% |
Free cash flow | 30.14M | 94.30% |
Previous close
$4.95
Day range
$4.88 - $5.05
Year range
$3.97 - $7.62
Market cap
1.52B USD
Avg Volume
2.20M
P/E ratio
51.65
Dividend yield
-
Primary exchange
NASDAQ
About
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann. Wikipedia
Founded
Feb 1991
Headquarters
Website
Employees
405
